Ignite Creation Date:
2024-05-06 @ 3:13 PM
Last Modification Date:
2024-10-26 @ 1:45 PM
Study NCT ID:
NCT04557956
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2020-09-18
Brief Title:
Testing the Addition of the Anti-cancer Drug Tazemetostat to the Usual Treatment Dabrafenib and Trametinib for Metastatic Melanoma That Has Progressed on the Usual Treatment
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Organization Data
Organization:
National Cancer Institute NCI
Class:
NIH
Study ID:
NCI-2020-07044
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
National Cancer Institute NCI
Lead Sponsor Class:
NIH
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None